• OPEN AN ACCOUNT
Indian Indices
Nifty
24,334.20 -1.75
(-0.01%)
Sensex
80,242.24 -46.14
( -0.06%)
Bank Nifty
55,087.15 -304.10
( -0.55%)
Nifty IT
35,794.95 -125.45
( -0.35%)
Global Indices
Nasdaq
40,538.66 290.07
(0.72%)
Dow Jones
5,579.50 29.75
(0.54%)
Hang Seng
36,006.39 166.40
(0.46%)
Nikkei 225
8,494.85 31.39
(0.37%)
Forex
USD-INR
85.20 -0.17
(-0.20%)
EUR-INR
96.93 -0.07
(-0.07%)
GBP-INR
113.83 0.22
(0.19%)
JPY-INR
0.60 0.00
(0.27%)

EQUITY - MARKET SCREENER

Tata Consultancy Services Ltd
Industry :  Computers - Software - Large
BSE Code
ISIN Demat
Book Value()
532540
INE467B01029
206.8297364
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TCS
26.14
1256019.08
EPS(TTM)
Face Value()
Div & Yield %
132.78
1
3.57
 

USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
Apr 28,2025
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (“the Subsidiary”) from 16 April 2025 to 24 April 2025.

On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.